upsized-cb-for-indian-drug-maker

Upsized CB for Indian drug maker

Orchid Chemicals raises $175 million to grow its portfolio of drugs. Conversion premium set at 30%.
Indian drug maker Orchid Chemicals Pharmaceuticals became the latest company to take advantage of the current strong demand for convertible bonds on Monday when it set itself up for raising the equivalent of half its market capitalisation through an upsized CB.

The $400 million-market cap company is expected to raise a total of $200 million after it increased the base size of its five-year, zero-coupon deal to $175 million from $125 million, and kept the greenshoe at $25 million, a source close to the deal said last night.

The offer, which was arranged by Merrill Lynch, followed on the back of a small pre-deal roadshow during which the management did 10 meetings or calls...
¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222